Danish agency reopens compensation cases for rashes after Covid-19 vaccination

Five patients whose claims for compensation were rejected after they developed skin rashes following Covid-19 vaccination will have their cases reopened.

Danish agency reopens compensation cases for rashes after Covid-19 vaccination
Denmark's patient compensation agency is to reopen cases for a small number of patients who developed chronic rashes after being vaccinated against Covid-19. File photo: Philip Davali/Ritzau Scanpix

The patients developed hives (nældefeber in Danish), also known as urticaria: a red, bumpy skin rash that can be physically painful, after receiving Covid-19 vaccination.

Their initial compensation claims were rejected but will now be looked at again, agency Danish Patient Compensation (Patienterstatningen) said in a statement on Friday.

The cases relate to chronic hives as a possible side effect of vaccination with both the Pfizer and Moderna vaccines.

The rash is common and can occur following an infection or as a result of an allergic reaction to medication as well as insect bites or foods.

The compensation agency has reviewed 13 rejected claims and will reopen 5 of those claims, it said.

The agency has also decided to take a second look at a case of tinnitus as a side effect of vaccination with the AstraZeneca vaccine. A total of eight such rejected claims were reviewed.

AstraZeneca’s vaccine was only used for a limited time in the Danish national Covid-19 vaccination programme before being withdrawn. The Moderna and Pfizer jabs were the primary vaccines in the programme.

The director of the Danish Patient Compensation, Karen-Inger Bast, said that new knowledge is continually emerging in relation to the side effects.

“We reopen cases if it proves that patients might have the right to compensation after all. So they don’t need to keep themselves updated,” she said in the statement.

“The next step will be to assess whether patients have, for example, developed hives to such a serious extent that it can give compensation,” she said.

People with ongoing side effects are encouraged by Danish Patient Compensation to contact the agency.

“If you have a serious side effect, please contact us. That might be something like chronic hives or tinnitus with reduced hearing that coincided with having the vaccine,” she said.

READ ALSO: Over 1.5 million Danes vaccinated against influenza and Covid-19 during late 2022

Member comments

Log in here to leave a comment.
Become a Member to leave a comment.


Covid-19: Denmark decides against additional booster this winter

No additional booster vaccination against Covid-19 will be offered this winter, the Danish Health Authority confirmed on Wednesday.

Covid-19: Denmark decides against additional booster this winter

Together with an expert advisory group, the Health Authority has considered whether to offer vulnerable groups an extra booster vaccination against Covid-19 this winter.

People at higher risk of serious illness with the virus including those over the age of 85 will not be offered a further booster this winter, the authority has decided.

Denmark offered a booster in autumn 2022 to all people over the age of 50 and younger people considered vulnerable to the coronavirus.

The booster was backed up by data suggesting it improves protection against hospitalisation with Covid-19 by 74 percent, according to the Danish Health Authority.

READ ALSO: Danish research finds improved protection from updated Covid-19 vaccine

Infection numbers in Denmark are currently low.

“We have the highest vaccine uptake in Europe and the vaccines have proved to be effective, including for the elderly and most vulnerable. We are in a good place in the Covid-19 epidemic. We can only be pleased about this,” head of section and consultant physician Kirstine Moll Harboe said in the statement.

The health authority nevertheless expects immunity and effectiveness of vaccines to fall over time and will therefore develop a plan for a new booster vaccination campaign to take place in the autumn.